دورية أكاديمية
Impact of cytochrome P450 2D6 polymorphisms on decision-making and clinical outcomes in adjuvant hormonal therapy for breast cancer.
| العنوان: | Impact of cytochrome P450 2D6 polymorphisms on decision-making and clinical outcomes in adjuvant hormonal therapy for breast cancer. |
|---|---|
| المؤلفون: | Tan EY; Department of General Surgery, Tan Tock Seng Hospital, Singapore 308433, Singapore.; Lee Kong Chian School of Medicine, Singapore 308232, Singapore.; Institute of Molecular and Cell Biology, ASTAR, Singapore 138673, Singapore. ern_yu_tan@ttsh.com.sg., Bharwani L; Department of Medical Oncology, Tan Tock Seng Hospital, Singapore 308433, Singapore., Chia YH; Department of Medical Oncology, Tan Tock Seng Hospital, Singapore 308433, Singapore., Soong RCT; Cancer Science Institute of Singapore, National University of Singapore, Singapore 119077, Singapore., Lee SSY; Department of General Surgery, Tan Tock Seng Hospital, Singapore 308433, Singapore., Chen JJC; Department of General Surgery, Tan Tock Seng Hospital, Singapore 308433, Singapore., Chan PMY; Department of General Surgery, Tan Tock Seng Hospital, Singapore 308433, Singapore. |
| المصدر: | World journal of clinical oncology [World J Clin Oncol] 2022 Aug 24; Vol. 13 (8), pp. 712-724. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Baishideng Publishing Group Country of Publication: United States NLM ID: 101549149 Publication Model: Print Cited Medium: Print ISSN: 2218-4333 (Print) Linking ISSN: 22184333 NLM ISO Abbreviation: World J Clin Oncol Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Publication: 2014-: Pleasanton, CA : Baishideng Publishing Group Original Publication: Hong Kong : Baishideng Publishing Group |
| مستخلص: | Background: There are concerns that tamoxifen is less effective in Asian women because of the high prevalence of impaired function cytochrome P450 2D6 ( CYP2D6 ) polymor-phisms. Aim: To evaluate how knowledge of CYP2D6 genotype impacted the choice of hormonal agent and how CYP2D6 genotype and agent were associated with clinical outcomes. Methods: Eighty-two women were recruited. Seventy-eight completed CYP2D6 genotyping and were categorized into poor, intermediate (IM) and extensive or ultra metabolizer phenotypes. Women with poor metabolizer and IM phenotypes were recommended aromatase inhibitors as the preferred agent. Results: More than 70% of the women had an IM phenotype, 32% an extensive or ultra metabolizer phenotype, and 0% had a poor metabolizer phenotype. Regardless of genotype, more women opted for aromatase inhibitors. Overall, 80% of women completed 5 years of hormonal therapy. Five women developed recurrence, 3 contralateral breast cancer, 5 died, and 1 was diagnosed with a second primary cancer. Five-year recurrence-free and overall survival were slightly better in women with the extensive or ultra metabolizer phenotype compared to those with the IM phenotype, though not statistically significant [ P = 0.743, hazard ratio (HR): 1.441, 95% confidence interval (CI): 0.191 to 10.17 and P = 0.798, HR: 1.327, 95%CI: 0.172 to 9.915, respectively]. Women receiving aromatase inhibitors also appeared to have a better, but also nonsignificant, 5-year recurrence-free and overall survival ( P = 0.253, HR: 0.368, 95%CI: 0.031 to 0.258 and P = 0.292, HR: 0.252, 95%CI: 0.005 to 4.951, respectively). Conclusion: The IM phenotype was highly prevalent but was not associated with clinical outcome. Competing Interests: Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article. (©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.) |
| References: | N Engl J Med. 1998 Nov 26;339(22):1609-18. (PMID: 9828250) Ann Oncol. 2008 Aug;19(8):1423-1429. (PMID: 18407954) Pharmacogenomics. 2002 Mar;3(2):229-43. (PMID: 11972444) Lancet Oncol. 2008 Jan;9(1):45-53. (PMID: 18083636) Trends Pharmacol Sci. 1991 Mar;12(3):102-7. (PMID: 2053186) Clin Pharmacol Ther. 1992 Apr;51(4):388-97. (PMID: 1345344) Pathology. 2008 Apr;40(3):295-8. (PMID: 18428050) Br J Clin Pharmacol. 2000 Jul;50(1):31-4. (PMID: 10886115) J Clin Oncol. 2005 Dec 20;23(36):9312-8. (PMID: 16361630) Pharmacogenetics. 2000 Aug;10(6):567-70. (PMID: 10975611) Breast Cancer Res Treat. 1982;2(2):123-38. (PMID: 6184101) Clin Cancer Res. 2017 Apr 15;23(8):2019-2026. (PMID: 27797974) Clin Pharmacol Ther. 1999 May;65(5):570-5. (PMID: 10340923) Mol Pharmacol. 1994 Sep;46(3):452-9. (PMID: 7935325) Eur J Clin Pharmacol. 1991;40(6):553-6. (PMID: 1679392) Pharmacogenetics. 1995 Jun;5(3):159-64. (PMID: 7550367) JAMA. 2009 Oct 7;302(13):1429-36. (PMID: 19809024) J Clin Oncol. 2007 Nov 20;25(33):5187-93. (PMID: 18024866) N Engl J Med. 2009 Feb 12;360(7):679-91. (PMID: 19213681) J Natl Cancer Inst. 2008 May 7;100(9):642-8. (PMID: 18445827) J Natl Cancer Inst. 2003 Dec 3;95(23):1758-64. (PMID: 14652237) N Engl J Med. 2005 Dec 29;353(26):2747-57. (PMID: 16382061) J Clin Pharm Ther. 2001 Jun;26(3):205-11. (PMID: 11422605) J Natl Cancer Inst. 1996 Nov 6;88(21):1529-42. (PMID: 8901851) Clin Pharmacol Ther. 1993 Apr;53(4):410-8. (PMID: 8097442) Clin Pharmacol Ther. 2006 Jul;80(1):61-74. (PMID: 16815318) |
| فهرسة مساهمة: | Keywords: Breast cancer; Functional cytochrome P450 2D6 polymorphisms; Hormonal therapy |
| تواريخ الأحداث: | Date Created: 20220926 Latest Revision: 20220928 |
| رمز التحديث: | 20240628 |
| مُعرف محوري في PubMed: | PMC9476606 |
| DOI: | 10.5306/wjco.v13.i8.712 |
| PMID: | 36160461 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 2218-4333 |
|---|---|
| DOI: | 10.5306/wjco.v13.i8.712 |